Oncocross Co., Ltd.

382150 · KQ · Technology / Software - Infrastructure

3,055.00KRW+20.00 (+0.66%)

Price History

Full chart

Market Stats

Previous Close3,035.00

Open3,035.00

Day Range2,975.00 – 3,105.00

52-Week Range2,235.00 – 14,490.00

Volume33.24K

Market Cap45.98B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

50-Day Avg3,471.50

200-Day Avg6,211.35

About

Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular Disease; ODP9401 for metabolic disease; and ODP2201, ODP2301, and ODP2401 to treat oncology-related diseases. It has a collaboration agreement with various pharmaceutical companies, research institutes, and bio-techs. The company was founded in 2015 and is based in Seoul, South Korea.

Company Details

SectorTechnology
IndustrySoftware - Infrastructure
CEODr. Yi Rang Kim M.D., Ph.D.
Headquarters11, Saechang-ro, Seoul, South Korea, Korea
Websitehttps://www.oncocross.com

Leadership

Dr. Yi Rang Kim M.D., Ph.D.Founder & CEO · b. 1980
Jihoon Kang M.D., Ph.D.Chief Executive Officer
Xavier Chae M.B.A.CFO & Executive Director
Jong Bae Park Ph.D.VP & CTO
Dong-Myung Shin Ph.D.Head of AI Research & Executive Director

Financials

Income Statement

Currency: KRW	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	150.25M	91.52M	1.07B	370.46M
Growth (%)	-	-39.08%	+1071.49%	-65.45%
Cost of Revenue	115.60M	87.01M	350.13M	-
Gross Profit	34.64M	4.51M	1.07B	370.46M
Gross Margin	23.06%	4.93%	100.00%	100.00%
Operating Expense	10.03B	6.81B	8.04B	9.20B
Operating Income	-10.00B	-6.81B	-6.96B	-8.83B
Operating Margin	-6655.30%	-7440.64%	-649.58%	-2383.65%
EBITDA	-9.76B	-3.63B	-6.06B	-7.59B
EBITDA Margin	-6495.04%	-3965.56%	-564.98%	-2049.48%
Net Income	-10.20B	-4.21B	-6.48B	-8.93B
Net Income Margin	-6791.63%	-4604.70%	-604.66%	-2410.17%
R&D	5.93B	2.87B	2.96B	3.30B
R&D as % of Total Revenue	3944.37%	3137.09%	275.67%	889.90%
Interest Expense	76.49M	38.31M	18.79M	526.27M
Interest Expense % of Total Revenue	50.91%	41.86%	1.75%	142.06%

Balance Sheet

Currency: KRW	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	8.40B	17.59B	22.55B	28.96B
Total Liabilities	3.71B	1.10B	2.09B	15.58B
Total Equity	4.70B	16.49B	20.46B	13.37B
Cash	3.19B	11.64B	15.34B	2.80B
Net Debt	-	-	-	2.24B

Cash Flow

Currency: KRW	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-8.20B	-4.91B	-5.52B	-7.41B
Capital Expenditure	340.80M	24.68M	173.63M	3.33B
Free Cash Flow	-8.54B	-4.93B	-5.70B	-10.73B
FCF to OCF	104.16%	100.50%	103.14%	144.91%

Earnings

Report Date	Dec 31, 2024	Mar 31, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-
EPS Actual	-192.00	-189.68	-147.69	-170.27	-238.65	-216.84	-178.88
Surprise	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap45.98B

Enterprise Value28.04B

Trailing P/E0.00

Forward P/E0.00

Price / Sales116.25

Price / Book3.26

Revenue (TTM)395.50M

Gross Profit (TTM)351.87M

EBITDA-8.71B

Profit Margin0.00%

Operating Margin-4642.00%

Return on Equity-42.57%

Return on Assets-24.14%

Shares Outstanding12.20M

Shares Float7.27M

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%